Patent ID: 8722727
Filing Date: 2014-05-13
Classification: A61K,A61P,C07D

Abstract:
1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: R wherein W, X′, Y, and Z are independently selected from N and CR e provided that only one of W, X′, Y and Z is CR e ; R a) H; b) Halogen; c) NR d) NHC(O)R e) NHC(O)NR f) NHC(O)OR g) NO h) OR i) SR j) SO k) SO l) CN; m) C(O)R n) C(O)OR o) C(O)NR p) C(═NR q) C r) C s) C t) heterocyclyl, wherein the heterocyclyl is a 4- to 6-membered saturated or unsaturated non-aromatic ring having 1, 2 or 3 heteroatoms selected from N, O or S, attached through a carbon or nitrogen on the ring, and optionally substituted on a ring carbon with 1 to 2 substituents independently selected from N(R u) aryl, wherein aryl is phenyl or naphthyl and aryl is unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, N(R v) heteroaryl, wherein heteroaryl is a 5- or 6-membered monocyclic aromatic ring or 9- or 10-membered bicyclic aromatic ring having 1, 2 or 3 heteroatoms selected from N, O or S, attached through a ring carbon or nitrogen, and optionally substituted on a ring carbon that is not the point of attachment, with 1 or 2 substituents independently selected from halogen, CF R R R R m is 0 or 1; n is 0 or 1; p is 0 or 1; T is NR R R R a) H; b) C c) C d) C(O)R e) C(O)OC f) C(O)NHR g) C(═NH)R h) C(═NR R R R R a) hydrogen, b) C c) C d) C e) aryl, wherein aryl is phenyl or naphthyl and said aryl is unsubstituted or substituted with 1 to 3 substituents selected from C f) heteroaryl, wherein heteroaryl is as defined above in the definition of R R R R a) H, b) C c) C d) C(O)R e) C(O)NHR R R R X is O or H, H; each R